GW Pharma to start Phase II/III trial of Dravet Syndrome drug Epidiolex in H2 2014
Dravet Syndrome is also known as Severe Myoclonic Epilepsy of Infancy (SMEI), a rare and catastrophic treatment-resistant form of childhood epilepsy. Following confirmation from FDA, the company intends